Q3 2023 EPS Estimates for AngioDynamics, Inc. (NASDAQ:ANGO) Reduced by Zacks Research

AngioDynamics, Inc. (NASDAQ:ANGOGet Rating) – Analysts at Zacks Research dropped their Q3 2023 earnings estimates for AngioDynamics in a report released on Tuesday, January 17th. Zacks Research analyst D. Dey now anticipates that the medical instruments supplier will earn ($0.01) per share for the quarter, down from their prior forecast of $0.01. The consensus estimate for AngioDynamics’ current full-year earnings is $0.01 per share. Zacks Research also issued estimates for AngioDynamics’ Q3 2024 earnings at $0.01 EPS, Q4 2024 earnings at $0.06 EPS, FY2024 earnings at $0.10 EPS, Q1 2025 earnings at $0.03 EPS and Q2 2025 earnings at $0.06 EPS.

A number of other brokerages also recently issued reports on ANGO. StockNews.com began coverage on shares of AngioDynamics in a report on Wednesday, October 12th. They set a “hold” rating on the stock. Raymond James lowered their price target on shares of AngioDynamics from $25.00 to $22.00 and set a “strong-buy” rating on the stock in a report on Friday, January 6th.

AngioDynamics Stock Performance

Shares of NASDAQ ANGO opened at $13.32 on Friday. The company’s fifty day moving average price is $13.34 and its 200 day moving average price is $17.49. AngioDynamics has a 1 year low of $11.71 and a 1 year high of $24.87. The company has a market capitalization of $521.26 million, a PE ratio of -16.05 and a beta of 0.66. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.30 and a current ratio of 2.16.

Hedge Funds Weigh In On AngioDynamics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC lifted its holdings in AngioDynamics by 0.9% during the third quarter. Allspring Global Investments Holdings LLC now owns 166,645 shares of the medical instruments supplier’s stock valued at $3,409,000 after purchasing an additional 1,560 shares in the last quarter. Bridgewater Associates LP lifted its holdings in AngioDynamics by 10.1% during the second quarter. Bridgewater Associates LP now owns 59,819 shares of the medical instruments supplier’s stock valued at $1,157,000 after purchasing an additional 5,467 shares in the last quarter. Loomis Sayles & Co. L P lifted its holdings in AngioDynamics by 10.6% during the second quarter. Loomis Sayles & Co. L P now owns 1,400,992 shares of the medical instruments supplier’s stock valued at $27,109,000 after purchasing an additional 134,075 shares in the last quarter. Frontier Capital Management Co. LLC lifted its holdings in AngioDynamics by 9.2% during the second quarter. Frontier Capital Management Co. LLC now owns 314,595 shares of the medical instruments supplier’s stock valued at $6,087,000 after purchasing an additional 26,538 shares in the last quarter. Finally, Envestnet Asset Management Inc. lifted its holdings in AngioDynamics by 7.1% during the second quarter. Envestnet Asset Management Inc. now owns 51,879 shares of the medical instruments supplier’s stock valued at $1,004,000 after purchasing an additional 3,441 shares in the last quarter. 94.94% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Company Profile

(Get Rating)

AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.

Featured Articles

Earnings History and Estimates for AngioDynamics (NASDAQ:ANGO)

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.